Health TrialsbyHealthPanel

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

ConditionEndophthalmitis
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age40+
SponsorJason Ahee, M.D.

About this trial

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

visually significant cataracts

Disqualifiers

allergy to fluoroquinolones, cobalamin (B12)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Moxifloxacin

    Drug

    Intracameral injection

  • Placebo

    Drug

    intracameral injection

Treatment groups

60,000 Participants
are divided into 2 treatment groups
Group A: Treatment groupActive comparator 1 intervention
Group B: Placebo groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Endophthalmitis after cataract surgery

Subjects will be followed after cataract surgery and have post-operative eye examinations to determine if infection in the eye (endophthalmitis) occurs during the study period.

Time frame
Subjects will undergo eye examinations at one day, one week, and one month post-operatively

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Jason Ahee, M.D.

Lead sponsor

Zion Therapeutics, LLC

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: